Skip to main content

Table 3 Prognostic factors for overall survival in HCC patients treated with combination treatment

From: Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma

Characteristics NO. (N2 = 132) mOS (month) Uni-variate HR (95%CI) p value Multi-variate HR1a (95%CI) p value Multi-variate HR2b (95%CI) p value
Gender (male/female) 112/20 21.7/15.8 1.095 (0.625–1.917) 0.752     
Age (< 60/≥60 years) 89/43 21.0/21.7 1.109 (0.720–1.708) 0.640     
Etiology (HBV/other than HBV) 109/23 21.0/26.3 1.154 (0.688–1.934) 0.587     
PLT (< 150/≥150 × 10E9/L) 74/58 21.7/21.4 0.970 (0.647–1.457) 0.885     
Albumin (< 35/≥35 g/L) 20/112 14.3/23.4 1.627 (0.959–2.763) 0.071     
Bilirubin (≥17/< 17 μmol/L) 51/81 15.9/27.1 1.573 (1.045–2.368) 0.030 1.397 (0.915–2.132) 0.121 1.371 (0.878–2.139) 0.165
AST (≥40/< 40 U/L) 69/63 14.8/32.7 2.008 (1.329–3.034) 0.001 1.859 (1.194–2.894) 0.006 1.854 (1.193–2.883) 0.006
ALT (≥40/< 40 U/L) 56/76 17.1/21.7 0.943 (0.624–1.427) 0.783     
AFP (≥200/< 200 ng/ml) 67/65 15.7/28.7 1.533 (1.017–2.310) 0.041 1.364 (0.869–2.142) 0.178 1.379 (0.884–2.152) 0.157
Ascites (with/without) 15/117 12.6/21.9 1.975 (1.093–3.569) 0.024 1.136 (0.470–2.764) 0.777 1.149 (0.477–2.769) 0.757
Child-Pugh score (5/6/≥7) 104/20/8 25.1/17.1/12.5 1.606 (1.149–2.244) 0.006 1.895 (1.150–3.123) 0.012 1.907 (1.160–3.137) 0.011
Tumor size (≥7/< 7 cm) 71/61 16.5/26.3 1.457 (0.966–2.199) 0.073     
No. of HCC nodules (≥2/1) 63/69 14.8/27.1 1.806 (1.200–2.718) 0.005 1.753 (1.134–2.709) 0.012 1.764 (1.138–2.733) 0.011
Sorafenib usage (after/before TACE) 43/89 22.9/21.0 0.932 (0.608–1.430) 0.747     
Vascularity (hypovascular/hypervascular) 44/88 15.0/25.1 2.003 (1.300–3.085) 0.002 2.103 (1.355–3.266) 0.001   
HFSR (non-responder/responder) 60/72 15.0/25.1 1.801 (1.201–2.700) 0.004 1.957 (1.281–2.991) 0.002   
Stratification
 Group A 52 29.1 1     1  
 Group BC 56 16.5 1.729 (1.085–2.758) 0.021    1.910 (1.167–3.127) 0.010
 Group D 24 11.9 3.166 (1.802–5.563) < 0.001    4.154 (2.311–7.465) < 0.001
  1. aMulti-variate HR1, variables of vascularity and 2HFSR60 were included in Cox-regression but not stratification
  2. bMulti-variate HR2, stratification was included after excepting vascularity and 2HFSR
  3. cGroup A: patients with both hypervascularity and HFSR-response; Group BC: patients with either hypervascularity or HFSR-response; Group D patients with hypovascularity and HFSR-nonresponse
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us